By Sophora Health Editorial Team · Medically reviewed · Published July 2026 · Last reviewed July 2026
If you have been spending any time in wellness spaces lately, you have encountered peptides. They are everywhere. They are being credited with everything from reversing skin ageing to eliminating hot flushes to rebuilding muscle that perimenopause has been steadily removing. Some of the claims are extraordinary. Some of the prices are too. Somewhere between the Instagram posts and the functional medicine clinic brochures, you are trying to work out what is real, what is promising but early, and what is marketing in a lab coat.
This article gives you that map. The evidence is stratified here by what it actually says, not by what someone is trying to sell you. Some peptides have real, peer-reviewed human trial data. Some have fascinating animal studies that have not yet translated to human evidence. Some are being discussed in clinics while the research catches up. You deserve to know which is which before you spend money or make health decisions.
What are peptides and why is everyone talking about them now?
Peptides are short chains of amino acids, the building blocks of proteins. Your body makes thousands of them naturally to act as signals: telling cells to produce collagen, triggering hormone release, regulating inflammation, instructing tissues to repair. The therapeutic idea is straightforward: if the body uses peptides as signals, perhaps supplying them from outside can prompt the body to do things it has become less efficient at with age. Some of the time, with some peptides, this works. The honest complication: the evidence is dramatically uneven, and perimenopause-specific human trial data is scarce for most peptides in this category.
Why perimenopause specifically?
The interest in peptides for perimenopause is not random. The menopausal transition creates a specific set of problems that conventional medicine addresses primarily through hormone replacement. For women who cannot or choose not to use HRT, the options narrow quickly. Peptides appeal because they promise targeted action: addressing skin collagen loss, joint deterioration, muscle decline, sexual function, and metabolic changes through biological signalling rather than hormone replacement. The logic is sound in principle. The execution is at very different stages of evidential maturity depending on which peptide you are considering.
Perimenopause specifically creates conditions where several peptide signals become less reliable. Growth hormone secretion declines. Collagen synthesis slows. The kisspeptin neurons that regulate the reproductive hormone axis become dysregulated, driving hot flushes. Insulin signalling becomes less efficient. The peptide field is, at its best, trying to address exactly these documented changes. At its worst, it is attaching clinical-sounding language to products that have no relevant human evidence.
The peptide field is sitting somewhere between genuinely exciting science and a wellness gold rush. Both descriptions are accurate. The job is to know which peptide sits in which category before you spend money or make decisions.
Someone important to you needs this too.
WhatsAppiMessageCopy LinkEmail
The peptides with actual human evidence
Collagen peptides: the one most people already have in their kitchen
Oral collagen peptides are the most evidence-backed peptides in this entire field, and the ones least likely to be discussed in the more dramatic wellness content. They are cheap, widely available, classified as dietary supplements, and not particularly glamorous. They are also genuinely supported by human clinical trial data.
A 12-month randomised controlled trial found that 5 grams of collagen peptides daily significantly improved bone mineral density in postmenopausal women compared to placebo. This matters because bone loss accelerates during perimenopause, starts before oestrogen fully declines, and is one of the most consequential long-term effects of the transition. The collagen peptide finding does not replace HRT or prescribed osteoporosis medication where those are clinically indicated, but it is a real, evidence-backed addition to a bone health approach.
A 2025 Journal of Microbiology and Biotechnology RCT found significant improvements in skin quality with oral collagen peptides. A 2025 Journal of Clinical Medicine study examined oral collagen peptides specifically for genitourinary syndrome of menopause. Multiple RCTs in adults aged 40-65 have found consistent improvements in skin elasticity, hydration, and density with daily supplementation of 2.5 to 5 grams. The evidence here is the most mature in the peptide field, the safety record is excellent, and the cost is accessible. If there is a peptide argument to start with, this is it.
GHK-Cu: the copper peptide with skin evidence
GHK-Cu is a naturally occurring copper peptide that the body produces itself, declining with age. It is found in blood plasma, saliva, and urine, and it has a significant regulatory function: influencing gene expression in a way that affects tissue repair, inflammation, and collagen synthesis. For women losing up to 30% of skin collagen in the first five years after menopause, this is where the clinical interest sits.
The topical evidence is real. A 2024 RCT of 60 women aged 40-65 applying 0.1% GHK-Cu cream twice daily for 12 weeks found a 31% reduction in wrinkle depth and 28% improvement in skin elasticity versus placebo. Collagen density on ultrasound increased 15.6%. A 2025 meta-analysis of seven RCTs involving 456 participants confirmed standardised improvements in wrinkle and skin quality outcomes. This is not animal data dressed as human evidence. It is actual placebo-controlled trial data in the relevant age group.
The important caveat: the clinical evidence is specifically for topical application. Injectable GHK-Cu and the ambitious systemic claims being made for it are ahead of the evidence. As a topical skincare ingredient for a woman in perimenopause losing skin collagen rapidly, GHK-Cu has a legitimate case. As a systemic anti-ageing intervention, the evidence does not yet support the claims being made.
Semaglutide and GLP-1 receptor agonists: for metabolic and weight changes
GLP-1 receptor agonists are not typically framed as peptide therapy in wellness spaces, but they are peptides. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) work by mimicking glucagon-like peptide-1, a naturally occurring gut hormone that regulates appetite, insulin secretion, and blood sugar. For perimenopausal women experiencing insulin resistance, visceral fat accumulation, and metabolic changes driven by oestrogen decline, the mechanism is directly relevant.
A 2024 Mayo Clinic study found that combining semaglutide with hormone therapy produced greater weight loss results than either alone in postmenopausal women. The evidence for GLP-1 agonists in weight management is the strongest in this entire category. They are prescribed medications, not supplements. They have real side effects including nausea and gastrointestinal symptoms, plus the documented concern that they reduce lean muscle mass alongside fat. For perimenopausal women already losing muscle through hormonal decline, this matters.
A 2025 scoping review in Cureus found dual-acting agents like tirzepatide, targeting both GLP-1 and GIP receptors, produced greater reductions in weight and insulin sensitivity than GLP-1-only agents. The perimenopause application is legitimate. The approach requires clinical assessment, prescription, and monitoring. This is not a self-prescribing category.
The peptides with interesting early evidence
Kisspeptin: the one targeting the hormonal system directly
Kisspeptin is the most mechanistically compelling peptide in the perimenopause field, and the one most women have not yet heard of. It is the master regulator of the reproductive hormone axis: the signal that tells the pituitary to release FSH and LH, which drive oestrogen and progesterone production. Kisspeptin neurons are now understood to be the direct driver of vasomotor symptoms, specifically the KNDy neurons in the hypothalamus that become hyperactive during perimenopause as oestrogen declines. Hot flushes are, at their root, a kisspeptin-driven event.
This is why fezolinetant, the FDA-approved non-hormonal treatment for hot flushes, works: it targets the neurokinin B receptor on these same KNDy neurons. Kisspeptin analogues are attempting to regulate the upstream hormonal signalling more directly. A Phase 1 trial of MVT-602, a kisspeptin receptor agonist, found all women given it showed longer-duration LH and FSH elevation than those given native kisspeptin, suggesting a potential pathway to more normal hormonal patterning. Multiple Phase II trials are currently examining kisspeptin analogues for vasomotor symptom control and ovulation support.
The important qualifier: kisspeptin analogues are not commercially available. They are in clinical trials. The kisspeptin supplements being sold online bear no meaningful relationship to the peptides being studied in these trials. The mechanism is real and the research direction is genuinely exciting. The product market around it is, for now, mostly ahead of the evidence.
Sermorelin and growth hormone secretagogues
Sermorelin is a synthetic analogue of growth hormone releasing hormone. Growth hormone secretion declines with age. The argument for sermorelin in perimenopause is that this decline compounds with the hormonal transition to accelerate muscle loss, fat redistribution, and reduced sleep quality. Sermorelin stimulates the pituitary to produce growth hormone naturally rather than injecting growth hormone directly, which is its claimed safety advantage.
It is available as a compounded prescription medication in the US and some other markets. Human evidence for sermorelin specifically in perimenopausal women is limited, but a 2006 Clinics in Interventional Aging review found meaningful evidence for growth hormone restoration in adults with age-related decline. CJC-1295 and ipamorelin are frequently combined as growth hormone secretagogues with some clinical use, though the large menopausal-population trials needed to make strong recommendations do not yet exist. This is a supervised clinical therapy, not a supplement category.
PT-141 (Bremelanotide): for sexual function
PT-141 is the only peptide with FDA approval in a women’s hormonal health context. It is approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. It works on melanocortin receptors in the brain, the central pathways involved in arousal and desire, rather than on peripheral blood flow as Viagra does. This is a genuinely different mechanism from anything else available for low libido.
The caveat is specific: the FDA approval covers premenopausal women only. Perimenopausal and postmenopausal women are not covered in the approval label. Off-label clinical use exists, and some clinicians prescribe it for perimenopausal women with HSDD, but the formal evidence base for this population specifically is limited. It is given as a subcutaneous injection before anticipated sexual activity. Side effects include nausea, flushing, and blood pressure changes.
The peptides being sold but not yet evidenced
BPC-157
BPC-157 is the most widely discussed and most oversold peptide in the perimenopause wellness space. It is a synthetic 15-amino acid peptide from a protein found in human gastric juice. The preclinical data is genuinely interesting: over 35 animal studies show accelerated tendon, ligament, muscle, and gastrointestinal healing, with anti-inflammatory effects and dopamine and serotonin modulation.
The human evidence, however, is almost entirely absent. A 2024 systematic review published in the American Journal of Sports Medicine found clinical data to be limited, with in-human safety remaining unknown. A 2025 systematic review confirmed the total human evidence: one retrospective case series of 12 patients for knee pain, and a pilot study in two healthy adults. No randomised controlled trials exist in any indication.
The regulatory situation adds another layer. The FDA removed BPC-157 from its Category 2 compounding eligibility effective April 22, 2026, meaning licensed pharmacies in the US cannot legally compound it for prescriptions. HHS Secretary Kennedy indicated in early 2026 that approximately 14 of 19 Category 2 peptides may return to compounding eligibility. As of July 2026, the formal FDA publication has not been released. BPC-157 is also on the WADA Prohibited List under unapproved substances.
The joint pain and tissue repair problems that drive women toward BPC-157 during perimenopause are real. The evidence that BPC-157 addresses them in humans does not yet exist. The distinction matters.
MOTS-c and Epithalon
MOTS-c is a mitochondria-derived peptide with genuine research interest for metabolic function and muscle preservation, including a 2021 Nature Communications study on its role in age-dependent physical decline. Epithalon is a synthetic tetrapeptide with preclinical evidence for telomerase activation and circadian rhythm regulation. Both are being marketed for perimenopause with enthusiasm. Both lack human RCT data in any indication relevant to the menopausal transition. Both are worth watching as the research develops. Neither has enough evidence to recommend or dismiss with confidence yet.
What peptides look like around the world
The peptide conversation is shaped almost entirely by the US and Western European wellness market. This is worth naming because it creates a particular blind spot: the most heavily marketed peptides are those with the most commercially active ecosystems, not necessarily those with the most evidence. The women most likely to be offered peptide therapy are those with access to functional medicine clinics: a geographic and economic subset of the women who actually need help with perimenopause.
In Japan, where anti-ageing medicine is deeply integrated into mainstream healthcare, peptide-based skincare and certain targeted peptide therapies have been in clinical and cosmetic use for decades. GHK-Cu has been studied and used in Japanese dermatological practice longer than in Western markets. The Japanese approach tends to be more cautious about systemic peptide applications while being more accepting of topical ones, reflecting the stronger evidence base for topical formulations.
In China and across East Asia, traditional medicine frameworks around qi, kidney essence, and jing map closely onto the peptide argument: declining vital signals that need to be restored. Several traditional Chinese herbal compounds have been studied for hormonal signalling and tissue preservation in perimenopausal women, with real mechanistic overlap with what peptide researchers are investigating through a Western lens. The research from Chinese institutions, including the Shanghai Institute of Materia Medica, on peptide-like bioactive compounds in traditional herbs is an active and underpublicised area.
In Sub-Saharan Africa and South Asia, peptide therapy is essentially unavailable for the vast majority of women. The perimenopause conversation remains primarily one of HRT access and traditional plant medicine. This is not a deficit in the evidence base. It is a reflection of who the current evidence base has been built for. The women accessing collagen peptides from a Nigerian health supplement market are accessing a category that does have real evidence. The women being offered bespoke peptide protocols at a Johannesburg functional medicine clinic are receiving a much thinner evidence base at a significant price point.
In Latin America, interest in peptide therapy has grown rapidly, particularly in Brazil, Argentina, and Mexico, driven by proximity to the US wellness market and active longevity medicine communities. Brazilian dermatology in particular has been an early adopter of GHK-Cu and collagen peptide research, and Brazilian clinical trials appear in the published literature on skin outcomes. The peptide conversation in Latin America is more clinically integrated than in the US wellness model, with dermatologists and endocrinologists more likely to be involved than functional medicine practitioners operating outside mainstream healthcare.
The honest framework for making decisions
The peptide field in 2026 sits somewhere between a genuinely exciting emerging science and a wellness gold rush. Both descriptions are accurate and they coexist. Here is how to navigate it practically.
Start with what has evidence. Oral collagen peptides at 5 grams daily have the strongest safety record and the most relevant human data for perimenopause concerns including bone density and skin quality. GHK-Cu topically has real RCT data for skin outcomes in the relevant age group. These are the least glamorous options in the peptide conversation and the most defensible ones.
Distinguish between mechanism and evidence. A peptide can have a compelling biological mechanism, strong animal data, and essentially no human trial evidence. BPC-157 is the clearest example. The mechanism is interesting. The animal data is consistent. The human evidence is almost entirely absent. These are three different things and they are frequently conflated in peptide marketing.
Watch for the regulatory situation. BPC-157’s removal from US compounding eligibility in April 2026 is a signal worth taking seriously. The FDA’s position reflects the absence of human safety data, not an ideological opposition to peptide medicine. Regulatory status changes, and the picture may look different in 12 months. But sourcing peptides from unregulated suppliers to circumvent current restrictions is a genuinely different risk category from purchasing approved or legally compounded formulations.
The GLP-1 conversation belongs with your doctor, not a wellness clinic. Semaglutide has the strongest evidence in this category for perimenopausal metabolic changes. It is also a medication with real side effects and real contraindications, and the muscle mass loss concern is clinically meaningful for women already losing muscle through hormonal decline. If GLP-1 agonists are relevant to your situation, that conversation belongs with a clinician who can monitor outcomes rather than with a subscription service.
Sophora’s Doctor Prep document can help you take an organised account of the specific symptoms driving your interest in peptides, what you have read, and what questions you want answered, into a clinical conversation. The goal is not to present a shopping list to your doctor. The goal is to have an informed conversation about whether any of this is appropriate for your specific situation.
Questions you are probably asking
Can peptides replace HRT?
No, and this is important. HRT directly replaces declining oestrogen and progesterone. Most peptides target downstream effects of that decline: skin collagen loss, bone density, muscle mass, metabolic changes, sexual function. Addressing the downstream effects while the upstream hormonal decline continues is not the same as addressing the cause. Some women use both. The decision about HRT remains separate from peptide decisions, and HRT has a substantially stronger evidence base for most perimenopausal symptoms than any peptide currently available.
Are collagen peptides worth taking during perimenopause?
Of all the peptides discussed here, oral collagen peptides have the most defensible evidence for the specific concerns of perimenopause: bone density and skin quality. At 5 grams daily, they are safe, widely available, and reasonably priced. They will not address vasomotor symptoms, mood, or sleep. They are one piece of a much larger picture, but it is a piece with real evidence behind it.
Is BPC-157 safe?
The honest answer is that nobody knows, because human safety data is essentially absent. The preclinical data is interesting. The regulatory removal from US compounding eligibility in April 2026 reflects the FDA’s assessment that evidence of human safety is insufficient to justify compounding. The pro-angiogenic effects that make it appealing for tissue repair also raise theoretical concerns about tumour growth that have not been evaluated in humans. This is not a reason to dismiss it as a future therapy. It is a reason not to source research-grade compounds from unregulated suppliers now.
What should I actually ask my doctor?
The most productive question is not “what do you think of peptides.” It is: “I am experiencing these specific symptoms, skin changes, joint pain, muscle loss, metabolic changes, and low libido. What does the evidence actually support for each of these?” That conversation may lead to HRT, to collagen peptides, to GLP-1 discussion, or to other approaches with solid evidence. It grounds the conversation in what you are actually trying to address rather than in the peptide category as a concept.
You now know: Peptides are not one thing. Collagen peptides and GHK-Cu have real human RCT evidence. GLP-1 agonists have the strongest data for metabolic changes. Kisspeptin research is genuinely exciting and not yet commercially available. BPC-157 has compelling animal data and almost no human evidence. No peptide is FDA-approved for menopause symptom management.
One thing to do: If you want to start somewhere with evidence behind it, oral collagen peptides at 5 grams daily have the best evidence-to-risk ratio in this category. For everything else, bring a specific symptom question to a clinician rather than a peptide shopping list.
Hold onto this: The peptide field is sitting somewhere between genuinely exciting science and a wellness gold rush. Both descriptions are accurate. Knowing which peptide sits in which category is what changes how you spend your money and make your decisions.
Someone important to you needs this too.
WhatsAppiMessageCopy LinkEmail
The next step
Sophora’s Symptom Decoder and Hormone Map can help you identify which specific symptoms are driving your interest in peptides and what the evidence actually supports for each of them. Private. Account-bound. Never sold, never used for advertising, never used to train public AI models.
mysophora.com · One payment. Twelve months. No subscription.
The peptide field is sitting somewhere between genuinely exciting science and a wellness gold rush. Both descriptions are accurate. Knowing which peptide sits in which category is what changes how you spend your money and make your decisions.
Last reviewed: July 2026 · Review due: September 2026 · Not therapy. Not medical advice. For your own use and understanding only. · mysophora.com